Read More Pharma Industry News The inside story behind Samsung Bioepis’ European biosimilar takeover Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars. bySrinathJanuary 5, 2026